Cash, cash equivalents, and marketable securities were approximately $977.4M as of June 30. “The FDA’s priority review of our BLA for tividenofusp alfa and alignment on an accelerated approval path for DNL126 are key milestones highlighting the potential of our Transport Vehicle (TV) platform to catalyze a new class of blood-brain barrier-crossing therapeutics,” said Ryan Watts, Ph.D., CEO of Denali Therapeutics (DNLI). “With launch readiness in motion and a growing portfolio of TV-enabled enzyme, antibody, and oligonucleotide programs, Denali is poised to deliver meaningful treatments for people living with lysosomal, neurodegenerative, and other serious diseases.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Royalty Pharma appoints Ho, Weatherman to board of directors
- Denali Therapeutics: Promising Developments and Strategic Focus Drive Buy Rating
- Denali noted no FDA panel meeting in call with William Blair
- Denali Therapeutics’ Promising Developments and FDA Milestones Support Buy Rating
- Denali Therapeutics’ FDA Priority Review for New Therapy